MicroRNA-140-5p inhibits hepatocellular carcinoma by directly targeting the unique isomerase Pin1 to block multiple cancer-driving pathways

Xingxue Yan¹,²,*, Zhendong Zhu¹,²,*, Shenmin Xu¹,²,*, Li-nan Yang¹,², Xin-Hua Liao¹,², Min Zheng¹,², Dayun Yang¹,², Jichuang Wang¹,², Dongmei Chen¹,², Long Wang¹,², Xiaolong Liu³, Jingfeng Liu³, Ruey-Hwa Chen⁴, Xiao Zhen Zhou¹,², Kun Ping Lu¹,²,⁵ & Hekun Liu¹,²

Hepatocellular carcinoma (HCC) is the second leading cause of cancer related-death. As a major common regulator of numerous cancer-driving pathways and a unique therapeutic target, the prolyl isomerase Pin1 is overexpressed in a majority of HCCs, whereas the mechanism underlying Pin1 overexpression remains elusive. Here we find that miR-140-5p inhibits HCC by directly targeting Pin1 to block multiple cancer-driving pathways. Bioinformatics analysis, miRNA binding and functional assays identify that miR-140-5p directly interacts with the 3′ UTR of Pin1 and inhibits Pin1 translation. Furthermore, like stable Pin1 knockdown, moderate overexpression of miR-140-5p not only eliminates Pin1, but also inhibits cells growth and metastasis. Importantly, these effects of miR-140-5p are largely rescued by reconstitution of Pin1. Moreover, miR-140-5p inhibits multiple Pin1-dependent cancer pathways and suppresses tumor growth in mice. The clinical significance of these findings has been substantiated by the demonstrations that miR-140-5p is frequently down-regulated and inversely correlated with Pin1 overexpression in HCC tissues and cell lines. Given prevalent miR-140-5p downregulation in other cancers and major impact of Pin1 overexpression on activating numerous cancer-driving pathways including global miRNA downregulation, the miR-140-5p/Pin1 axis may play a major role in tumorigenesis and offer promising therapeutic targets for HCC and other cancers.

Hepatocellular carcinoma (HCC) is the second leading cause of cancer related-death, although it is the sixth most frequently diagnosed cancer of men and eleventh one of women worldwide, resulting in more than 600,000 deaths and almost as many estimated new cases each year¹,². The 5-year survival rate is still limited to 20–30% in HCC patients after surgery, mainly due to the frequent presence of metastasis, which is the fundamental feature of malignant tumors⁴–⁵. Despite much progress has been made in understanding the etiology and consequence of HCC, there is still no effective treatment available for this life-threatening disease⁶–⁷. Therefore, novel therapeutic strategies to efficiently interfere the progression of HCC patients are urgently needed⁸–⁹. In this regard, epigenetic
changes in microRNAs and their target gene expression may provide new tools and opportunities for the diagnosis and treatment of HCC.

Protein phosphorylation on certain Pro-directed serine or threonine residues (pSer/Thr-Pro) is a central common signaling mechanism in cell proliferation and transformation, which is regulated by many kinases and phosphatases. These phosphorylated proteins uniquely adopt cis and trans conformations, a process that is catalysed by the unique peptidyl-prolyl cis/trans isomerase Pin1. Pin1 specifically binds to certain Pro-directed phosphorylated serine or threonine (pSer/Thr-Pro) motifs using its WW domain, and catalyzes cis-trans isomerization of certain substrates using its PPIase domain. Such pin1-catalysed conformational regulation, which can be detected by cis and trans conformation-specific antibodies, has a major effect on numerous phosphorylated proteins in cancer signaling pathways. It has been shown that Pin1 is overexpressed and/or overactivated in the majority of human cancers including breast, lung, colon, prostate and liver cancers, with its levels being correlated with poor outcomes in cancer patients. In contrast, genetic single nucleotide polymorphism that reduces Pin1 expression is associated with reduced cancer risk for numerous cancers. Moreover, Pin1 activates more than 43 oncogenes and also inactivates at least 20 tumor suppressors, leading to activation of multiple oncogenic pathways synchronously. Thus, inhibiting Pin1 could obtain the unique ability to block multiple cancer-driving pathways concurrently. Notably, Pin1 is overexpressed in more than 70% human HCC patients and Pin1 overexpression transforms normal liver cells, where Pin1 genetic knockdown inhibits HCC tumor growth induced by HBx and multiple Pin1-dependent cancer pathways in HCC. Moreover, Pin1 overexpression results in global downregulation of microRNAs (miRNAs) in HCC. However, although Pin1 has been shown to be regulated by multiple mechanisms notably in breast cancer, little is known so far about the molecular mechanism of Pin1 overexpression in HCC.

Despite the potential biological significance. In order to demonstrate that miR-140-5p indeed targets Pin1, we performed a luciferase reporter assay, as described. The four miRNA mimics were cotransfected with the pmirGLO vector bearing wild-type or mutated miR-140-5p binding site of Pin1 3′ UTR. We observed that as shown for the positive control miR-200b and miR-200c, miR-140-5p inhibited the luciferase activity of the pmirGLO plasmid with wild-type 3′ UTR of Pin1 by about 50% (Fig. 1d), whereas mutation of miR-140-5p seed region in Pin1 3′ UTR counteracted the regulating effects of miR-140-5p (Fig. 1e). To confirm that miR-140-5p indeed regulates Pin1 expression, we transiently transfected four different miRNA mimics into human HCC cells. Furthermore, like stable Pin1 knockdown, moderate overexpression of miR-140-5p in HCC cells not only reduced Pin1 expression, but also inhibited cells proliferation and metastasis, which were largely rescued by reconstitution of Pin1 that is resistant to miR-140-5p mediated inhibition. Importantly, such miR-140-5p overexpression also inhibited multiple Pin1-dependent cancer pathways and suppressed tumor growth of human HCC cells in mice. Moreover, miR-140-5p expression is frequently down-regulated and inversely correlated with Pin1 overexpression in human HCC tissues, as compared with those in adjacent non-cancerous liver tissues. These results together demonstrate for the first time that miR-140-5p inhibits HCC by directly targeting the unique isomerase Pin1 to block multiple cancer-driving pathways and suggest that such a new pathway could be explored for the diagnosis and treatment of HCC.

**Results**

**Pin1 is a direct target for miR-140-5p in HCC.** Pin1 overexpression has been observed in ~70% human HCC patients, but little is known about molecular mechanisms leading to Pin1 overexpression in HCC. To identify whether Pin1 is regulated by miRNAs, we used miRNA target prediction programs miRnada, TargetScan and PITA to search for candidate miRNAs for Pin1 (Supplementary Table S1). We identified eleven candidate miRNAs with the potential targeting the 3′ UTR of Pin1, which were predicted by at least two of the three bioinformatics databases. Among these eleven candidates, miR-140-5p and miR-200s (miR-200b/200c/429) were predicted by all of the three databases (Fig. 1a) and found to be frequently downregulated in HCC.

However, the cellular targets and mechanisms of miR-140-5p in the regulation of downstream signal pathways in HCC are not fully understood.

In this article, we used bioinformatics databases to identify candidate miRNAs targeting the 3′ UTR of Pin1 mRNA and demonstrated that miR-140-5p inhibited Pin1 expression at the translational level in human HCC cells. Furthermore, like stable Pin1 knockdown, moderate overexpression of miR-140-5p in HCC cells not only reduced Pin1 expression, but also inhibited cells proliferation and metastasis, which were largely rescued by reconstitution of Pin1 that is resistant to miR-140-5p mediated inhibition. Importantly, such miR-140-5p overexpression also inhibited multiple Pin1-dependent cancer pathways and suppressed tumor growth of human HCC cells in mice. Moreover, miR-140-5p expression is frequently down-regulated and inversely correlated with Pin1 overexpression in human HCC tissues, as compared with those in adjacent non-cancerous liver tissues. These results together demonstrate for the first time that miR-140-5p inhibits HCC by directly targeting the unique isomerase Pin1 to block multiple cancer-driving pathways and suggest that such a new pathway could be explored for the diagnosis and treatment of HCC.
Figure 1. Pin1 is a direct target of miR-140-5p in HCC. (a) Bioinformatic prediction of candidate miRNAs targeting the Pin1 3′ UTR. (b) Schematic diagram showing the predicted binding region of miRNAs in Pin1 3′ UTR. (c) The predicted binding sites for miR-140-5p in Pin1 3′ UTR. The red nucleotides are the seed-pairing target sites of miRNAs. (d) Bioinformatic analyses show Pin1 as a promising target of miR-140-5p (top panel) and miR-140-5p reduces Pin1 expression (bottom panel), as assayed by a luciferase reporter. The seed sequences of miR-140-5p within the Pin1 3′ UTR are evolutionarily highly conserved across mammals as marked red. Capitalized letters are the conserved binding sites that directly interact with miR-140-5p. Dual-luciferase assay showed that miR-140-5p and miR-200s reduce luciferase activity by about 50%. (e) MiR-140-5p targets wild-type Pin1 3′ UTR, but not its mutant. Luciferase constructs bearing a Pin1 3′ UTR (WT) or Pin1 3′ UTR containing mutated binding sequences of miR-140-5p (Mut) were cotransfected with miR-140-5p. Results showed that miR-140-5p reduces luciferase activity by 50%, but that was abolished when miR-140-5p binding sequences on Pin1 3′ UTR was mutated. (f) MiR-140-5p downregulates Pin1 and cyclin D1 expression, as detected by Western blot analysis. β-actin served as loading control. (g) MiR-140-5p downregulates Pin1 at the translational level. Huh7 cells were infected with lentiviruses expressing miR-140-5p followed by selection with indicated concentration of puromycin. The expression of miR-140-5p and Pin1 protein were significantly increased and decreased, respectively, while Pin1 mRNA level had no significant change. In all panels, bar graphs represent mean ± SEM of three independent experiments. The statistical significance of all tests was accepted for P < 0.05.
miR-140-5p also downregulated Pin1 expression in PLC/PRF/5 cells (Supplementary Fig. S1a). Taken together, these results support that Pin1 is a miR-140-5p downstream target.

**Moderate overexpression of miR-140-5p potently inhibits cell growth, colony formation, migration and invasion of human HCC cells.** Pin1 overexpression in human HCC is an independent factor for poor prognosis, correlating with larger tumor size and increased portal vein invasion in HCC48. Given the downregulation of Pin1 by miR-140-5p in HCC cells, we wondered whether such regulation has any functional impact on HCC cells. Moderate Pin1 overexpression in non-transformed human mammary epithelial HMLE cells induces the epithelial–mesenchymal transition (EMT)23, which was linked to invasion and metastasis of cancer49. We hypothesize that miR-140-5p-mediated Pin1 downregulation might cause the mesenchymal-epithelial transition (MET) in HCCs. To test this possibility, we stably infected Huh7 HCC cells with lentiviruses expressing miR-140-5p, followed by examining its effect on cell phenotypes. MiR-140-5p overexpression not only resulted in a significant reduction in Pin1 protein levels, as compared with vector controls, but also induced epithelial-like morphological feature in Huh7 cells (Fig. 2a). To confirm that miR-140-5p-expressing cells have undergone the MET, we detected the expression of epithelial and mesenchymal markers using Western blot analysis. Indeed, miR-140-5p overexpression drastically upregulated protein levels of the epithelial marker E-cadherin, but downregulated expression of the mesenchymal markers MMP9 and vimentin (Fig. 2a and Supplementary Fig. S2a). These results are consistent with the notion that miR-140-5p overexpression causes the MET.

To further support this opinion, we carried out cell proliferation assay, colony formation assay and transwell assay for testing the migration and invasion of Huh7 cells. Strikingly, we found that miR-140-5p overexpression in Huh7 cells led to a significant decrease in the capacity of cell growth (Fig. 2b), migration and invasion (Fig. 2c), and colony formation (Fig. 2d). If these effects are specific due to miR-140-5p-mediated Pin1 downregulation, we expressed a Pin1 mutant construct that is resistant to miR-140-5p due to lack of the Pin1 3′UTR would rescue the phenotypes. Indeed, miR-140-5p-resistant Pin1 significantly rescued the expression of vimentin and cyclin D1, as a functional readout for Pin1 (Fig. 2a), as well as rescued the ability of miR-140-5p overexpression to inhibit the growth capability (Fig. 2b and d) and to reduce the migratory and invasive capacity (Fig. 2c) of Huh7 cells. To further demonstrate the function of miR-140-5p in HCC, we carried out cell proliferation assay and transwell assay in PLC/PRF/5 cells. Notably, we found that miR-140-5p overexpression in PLC/PRF/5 cells significantly reduced the expression of vimentin and cyclin D1 (Supplementary Fig. S2b), and decreased cell growth (Supplementary Fig. S2c) and migration (Supplementary Fig. S2d), which were significantly rescued by expression of miR-140-5p-resistant Pin1, consistent with the above results in Huh7 cells (Fig. 2a,b and c). The lack of a full rescue is likely due to that miR-140-5p has multiple targets such as FGF9 and TGFβR1, as shown for most other miRNAs50. Since the original hypothesis of this study is that Pin1 is a downstream target of miR-140-5p, we would expect that Pin1 knockdown might not further enhance the tumour suppressive functions of miR-140-5p in Huh7 cells as detected by transwell migration assay. Indeed, combination of Pin1 knockdown and miR-140-5p overexpression did not significantly enhance the migratory capacity of miR-140-5p in Huh7 cells (Supplementary Fig. S2e). Taken together, these data demonstrate that miR-140-5p not only down-regulates Pin1, but also inhibits cell growth, colony formation, migration and invasion of human HCC cells in vitro.

**Effect of Pin1 knockdown on HCC cells.** If the above functional effects of miR-140-5p on cell growth, colony formation, migration and invasion of human HCC cells is due to miR-140-5p-mediated Pin1 downregulation, we would expect that Pin1 genetic knockdown would produce the similar phenotypes. To address this possibility, we stably silenced Pin1 function by infecting Huh7 cells with lentiviruses expressing a validated shRNA of Pin1 followed by examining its effect on cell phenotypes, as described32. Indeed, stable knockdown of Pin1 in Huh7 cells induced the epithelial-like morphological feature (Supplementary Fig. S3a), drastically upregulated expression of the epithelial marker E-cadherin and downregulated expression of the mesenchymal marker vimentin (Supplementary Fig. S3a). Furthermore, Pin1 knockdown also significantly inhibited cell proliferation, migratory and invasive behavior of HCC cells, as detected by MTT assay (Supplementary Fig. S3b), wound healing assay (Supplementary Fig. S3c) and transwell assay (Supplementary Fig. S3d). Moreover, Pin1 knockdown also markedly inhibited cell colony formation of HCC cells (Supplementary Fig. S3e). Notably, some of these Pin1 knockdown phenotypes are similar to those observed independently as described32. Thus, these results indicate that both Pin1 shRNA and miR-140-5p lead to similar phenotypes, inhibiting cell growth, colony formation, migration and invasion of HCC cells in vitro.

**MiR-140-5P blocks multiple Pin1-dependent cancer pathways simultaneously.** We and others have shown that Pin1 regulates multiple cancer pathways50. To further support the notion that miR-140-5p exerts potent anticancer activity against HCC by targeting Pin1, we examined the effects of miR-140-5p on a set of oncoproteins, which are substrates for Pin1 and whose protein stability is maintained by Pin1, with Pin1 knockdown as a positive control. Like Pin1 knockdown (Fig. 3a), moderate overexpression of miR-140-5p caused a significant decrease in the abundance of Pin1 and its downstream oncoproteins, including cyclin D133, CDK223, AKT33, pAKT47332, ERK28, pERK2824, and NF-κB p6548 (Fig. 3b). Moreover, these effects were partially rescued by reconstitution of miR-140-5p-resistant Pin1 (Fig. 3b). Thus, miR-140-5p exerts potent anticancer activity against HCC by ablatting Pin1 and thereby blocking multiple cancer pathways simultaneously.

**MiR-140-5p inhibits HCC tumor growth by targeting Pin1 in vivo.** To demonstrate that miR-140-5p could inhibit HCC tumor growth by targeting Pin1 in vivo, we subcutaneously injected stable miR-140-5p- or miR-NC (negative control)-expressing Huh7 cells into the either flank of the same nude mice, followed by monitoring tumor growth for 8 weeks after implantation. The size of subcutaneous tumors originated from miR-140-5p-transduced Huh7 cells was dramatically smaller than that of miR-NC (negative control)-transduced cells,
as revealed by tumor growth curves, photographic illustration of final tumors or their weights (Fig. 4a, b and c). Moreover, miR-140-5p significantly decreased the abundance of Pin1 and its functional readout cyclin D1 in tumors as compared to controls (Fig. 4d), consistent with the above in vitro results (Figs 1f and 3c). Taken together, our data show that miR-140-5p has potent anti-tumor activity against HCC through targeting Pin1 to block multiple cancer pathways in vitro and in vivo.
MiR-140-5p is downregulated and correlated with Pin1 overexpression in HCC cell lines and human HCC tissues. To demonstrate the clinical significance of miR-140-5p-mediated Pin1 regulation in HCC, we first determined expression levels of miR-140-5p and Pin1 protein by qRT-PCR and Western blot assay, respectively, in normal human liver cell line LO2 and 7 human HCC cell lines HepG2, Huh7, Hep3B, PLC/PRF/5, MHCC-97H, HCCLM3, SMMC-7721. The normal human liver cell line LO2 had lower Pin1 levels but higher miR-140-5p levels, whereas the HCC cell lines examined had higher Pin1 levels but lower miR-140-5p levels (Fig. 5a, c and d). Statistical analysis revealed Pin1 protein levels were inversely correlated with miR-140-5p levels ($R = -0.6621$ and $P$ value $= 0.0263$) in normal and HCC cells (Fig. 5e). Next, we extended our experiments to the clinical samples obtained from HCC patients. By comparing HCC tumor tissues and paired adjacent non-cancerous liver tissues (ANLTs) of 25 HCC patients, we found that Pin1 was overexpressed in about 64%
(16/25; T 1-5) of HCC tissues (Fig. 5b and f), which was consistent with the previous findings29. We also found that miR-140-5p was markedly reduced in HCC tissue as compared with the paired ANLTs of 25 HCC patients (Fig. 5g), as shown by a separate study1. More importantly, we found a significantly inverse correlation between expression levels of Pin1 and miR-140-5p ($R = -0.5183$ and $P = 0.0080$) in human HCC samples (Fig. 5h), as expected from our above results in vitro and in vivo. These results indicate that loss of miR-140-5p is a major factor contributing to Pin1 overexpression in HCC, further supporting the significance of miR-140-5p-mediated regulation of Pin1 in HCC.

**Discussion**

It has been shown that Pin1 is markedly overexpressed in a wide range of human cancers, including breast cancer55, prostate cancer56, glioblastoma57 and HCC26,29,58. Pin1 overexpression promotes tumorigenesis by activating multiple cancer-driving pathways at the same time. High Pin1 expression has been shown to be an independent factor for cancer development and poor prognosis and is along with larger tumor size and increased portal vein invasion of HCC48. However, while mechanisms regulating Pin1 expression have been studied in other cancers28, molecular mechanisms leading to Pin1 overexpression in HCC and its impact on the malignancy of HCC are still unclear. This question is important given that HCC is one of the most lethal cancers with few therapeutic options. The present study uncovers for the first time that miR-140-5p directly targets Pin1 to block multiple cancer-driving pathways and exert potent antitumor activity in vitro and in vivo.

Recently, it has been shown that deregulation of miRNAs contributes to the tumorigenesis and progression of tumor1,39,60, and that miRNAs carry out their function by targeting multiple genes50. Notably, Takata et al. have shown that miR-140 acts as a liver tumor suppressor by directly targeting Dnmt1, and demonstrated that miR-140 is related to hepatocarcinogenesis61. Hao Yang et al. found that miR-140-5p is strikingly down-regulated in HCC and that ectopic miR-140-5p expression inhibits the capacity of HCC tumor growth and metastasis by targeting TGFβR1 and FGF91.

In the present study, our bioinformatics analysis and miRNA binding and functional assays showed that miR-140-5p directly interacted with a conserved target sequence in the 3’UTR of Pin1 mRNA and inhibited Pin1 translation in human HCC cells. Furthermore, like Pin1 knockdown, miR-140-5p exerted potent anticaner activity against HCC by targeting Pin1 to block multiple Pin1-dependent cancer pathways simultaneously, thereby suppressing the migratory, invasive and proliferous capacity of HCC cells. Importantly, these effects of miR-140-5p were significantly, but not fully rescued by reconstitution of Pin1 resistant to miR-140-5p. These results are consistent with the previous findings that miR-140-5p has other targets such as TGFβR1 and FGF91. Interestingly,
some downstream targets of TGFβR1 and FGF9 such as TGF-β and the ERK/MAPK signaling pathways62,63 are regulated by Pin128. For example, in our study, miR-140-5p suppressed the expression of a few endogenous ERK/MAPK pathway-related proteins (such as ERK and pERK) (Fig. 4b) by ablating Pin1 and thereby inhibited the activity of ERK/MAPK signaling pathway. Therefore, Pin1 is likely important for miR-140-5p to affect HCC growth and metastasis. Importantly, we found that miR-140-5p also inhibits many other Pin1 substrate oncoproteins. Moreover, miR-140-5p decreased tumor growth of HCC by ablating Pin1 and its downstream target cyclin D1 in vivo. Finally, expression of miR-140-5p was markedly reduced and correlated with Pin1 overexpression in human HCC tissues and cell lines compared to their respective normal controls. These results together indicate that loss of miR-140-5p contributes to tumor growth and metastasis of HCC, at least in part, through the up-regulation of Pin1 and its multiple cancer-driving pathways simultaneously.

Interestingly, in addition to HCC1, miR-140-5p has been shown to be gradually lost along with tumor progression and related to metastatic disease in ovarian cancer41, colorectal cancer45, lung cancer46, tongue cancer47. Notably, Pin1 overexpression has been shown to reduce pre-miRNA export from the nucleus, resulting in global downregulation of miRNAs in liver cancer33. Therefore, the deregulation of the miR-140-5p/Pin1 interaction may represent an aggressive molecular lesion in cancer development by resulting in global reduction of miRNA and activation of numerous cancer-driving pathways, offering novel therapeutic targets not only for HCC, but also for other cancers.
Materials and Methods

Cell cultures. The normal human liver cell line LO2, and HCC cell lines HepG2, Huh7, Hep3B, PLC/PRF/5, MHCC-97H, HCCLM3, SMMC-7721 were purchased from the Type Culture Collection of the Chinese Academy of Sciences, Shanghai, China. LO2, Huh7, MHCC-97H, HCCLM3 were cultured in DMEM (Invitrogen), supplemented with 1% antibiotics (GIBCO) and 10% fetal bovine serum (GEMINI). The HepG2, Hep3B, PLC/PRF/5 cell lines were cultured in MEM (Invitrogen) supplemented with 10% FBS and 1% antibiotics. The SMMC-7721 was cultured in RPMI1640 (Invitrogen) with 1% Penicillin-Streptomycin and 10% FBS. All cells were cultured in 5% CO2 humid atmosphere at 37°C.

Clinical specimens. All studies involving human subjects were approved by the Institutional Review Board at Mengchao Hepatobiliary Hospital of Fujian Medical University, and performed in accordance with the relevant guidelines and regulations. Informed consent was obtained from all patients at Mengchao Hepatobiliary Hospital of Fujian Medical University before we carried out our studies. Matched fresh HCC tissues and adjacent non-cancerous liver tissues (ANLTs) of 25 HCC patients were collected at the time of hepatic resection and immediately frozen in liquid nitrogen and then stored at −80°C for RNA and Protein isolation. All HCC tissues were further confirmed by pathological examination. The clinicopathological characteristics of these fresh samples were provided in the Supplementary Table S2.

Oligonucleotides and Plasmids. MiRNA-140-5p, miRNA-200b, miRNA-200c, miRNA-429 and NC mimics were synthesized by Genepharmaceutical Co. (Shanghai, China). The oligonucleotides of these miRNA mimics are shown in the Supplementary Table S3.

Luciferase Reporter Assays. For the reporter assays, HEK293T cells (5×10^4) were used. The miRNA mimics (50 nM) were transfected into cells using TurboFect Transfection Reagent (Thermo Scientific) according to the directions of manufacturer. The cells (5×10^4) were plated in each well of the 24-well plate and incubated overnight. Mimics and TurboFect were mixed in Opti-MEM, coincubated for 20 min, and then added to the 24-well plate. Cells were cultured with the mixture in medium and harvested at an indicated time point for specific experiments.

Western blot analysis. Total proteins were extracted by placing cell lines and HCC specimens in lysis buffer at 4°C for 30 min. The protein samples were separated by using SDS-polyacrylamide gel electrophoresis (PAGE) and then transferred onto PVDF membrane. The PVDF membranes were incubated with primary antibodies, anti-Pin1 (home made), anti-MMP9 (1:200; D261999; Sangon Biotech), anti-E-cadherin (1:500; #3195S; Cell Signaling Technology), anti-vimentin (1:1,000; #3932S; Cell Signaling Technology), anti-cyclinD1 (1:500; #2978S; Cell Signaling Technology), anti-CD2K (1:500; #2546S; Cell Signaling Technology), anti-Akt (1:1,000; #9272S; Cell Signaling Technology), anti-p-Akt (Ser 473) (1:500; #9271S; Cell Signalling Technology), anti-ERK (1:500; 13-6200; Invitrogen), anti-pERK (1:1,000; #9101S; Cell Signaling Technology), anti-NCi-v-Bcl6 (1:1,000; #8242S; Cell Signaling Technology) and then probed with a secondary antibody (1:5,000; Merck Millipore), β-actin (1:8,000; #HC201-02; TransGen Biotech) or GAPDH (1:8,000; #HC301-02; TransGen Biotech) was used as a protein loading control.

Total RNA Isolation, RT-PCR, and Quantitative Real-time PCR. Total RNA was extracted from HCC specimens and cell lines using RNAsio Plus reagent (TaKaRa). Complementary DNA (cDNA) was reverse transcribed from the total RNA using PrimeScript™ RT reagent Kit with gDNA Eraser (TaKaRa). Quantitative Real-time PCR was performed using SYBR Premix Ex Taq (TaKaRa) according to the manufacturer's protocol. The primer sequences used in this study are provided in Supplementary Table S3. Total RNA containing miRNA was isolated from HCC specimens and cell lines using mirVana™ miRNA Isolation Kit (Invitrogen), and the reverse transcription reaction was performed using TaqMan® MicroRNA Reverse Transcription Kit (Invitrogen). Quantification of miR-140-5p was performed using TaqMan® MicroRNA
Assays (Invitrogen) in a reaction containing 10 ng of total cDNA following the manufacturer’s protocol and the specific primers for miR-140-5p was designed by Applied Biosystems. The relative expression of miRNA-140-5p in tumor tissues against ANLTs and among different cell lines was obtained by comparing the cycle threshold (Ct) values which were normalized by the internal control RNU6B (U6 snRNA). Each sample was detected in triplicates.

**Cell Proliferation, Cell Cycle, Cell Colony Formation assays.** Cell proliferation was determined by counting the number of cells or using 3-(4, 5-dimethylthiazol-2-yl)-2, 5- diphenyltetrazolium bromide (MTT) assays. For cell colony formation assays, HuH7 cells (4×10³) were seeded in each well of 6-well plates and cultured for 2 weeks at 5% CO₂, 37°C. The numbers of colonies per well were counted after staining with crystal violet. All studies were conducted with 3 replicates.

**In Vitro Wound Healing, Migration and Invasion Assays.** Cells (4×10³) were seeded into 12-well plate coated with Collagen. Until the cells reached 95% confluence, wound healing assays were carried out with a sterile 10 μL pipette tip to straightly scratch 2 lines through the confluent monolayer. The cells were cultured with fresh medium for another 48 h, and then photographed for calculating wound closure. The percent of wound closure was calculated using Image J software.

For migration assay, cells (5×10³) in serum-free medium were seeded into the upper chamber without matrigel (Merck Millipore), and 48 hours later, the cells in the upper chamber were removed. The number of cells that adhering to the lower membrane was counted after staining with 0.1% crystal violet. For the invasion assay, cells (5×10⁴) in serum-free medium were seeded into the upper chamber of the insert with matrigel (BD Biosciences), and 48 hours later, the cells in the upper chamber were removed. The number of cells that adhering to the lower membrane was counted after staining with 0.1% crystal violet. All studies were conducted with 3 replicates.

**HCC Mouse Model.** The hepatocellular carcinoma nude mice model was constructed as previously described. Briefly, cells (3×10⁶) were subcutaneously injected into the bilateral upper flank regions of the nude mice (3-4 weeks of age, female, BALB/c). Two month later, the mice were sacrificed when their tumor volume reached 1000 mm³, and the subcutaneous tumors were removed for calculating the size as follows: tumor volume (mm³) = (L × W²)/2, where L = long axis and W = short axis. BALB/c nude mice were housed in laminar flow cabinets with free access to food and water in Laboratory Animal Center of Fujian Medical University. All of animal experiments were performed in accordance with the animal protocols and regulations approved by FJMU Experimental Animal Ethics Committee of Fujian Medical University.

**Statistical Analysis.** Statistical analysis was performed using SPSS (v. 22.0, Chicago, IL). All data are presented as the mean ± SEM, and then two-tailed Student’s t test or analysis of variance test (ANOVA) was used to compare unpaired samples. Paired Student’s t test was used to compare paired groups of samples. The statistical significance of all tests was accepted for P < 0.05, P < 0.01 and P < 0.001.

**References**

1. Yang, H., Fang, F., Chang, R. & Yang, L. MicroRNA-140-5p suppresses tumor growth and metastasis by targeting transforming growth factor beta receptor 1 and fibroblast growth factor 9 in hepatocellular carcinoma. *Hepatology* 58, 205–217, doi: 10.1002/hep.26315 (2013).
2. Li, X. et al. Adenovirus-delivered CIAPIN1 small interfering RNA inhibits HCC growth in vitro and in vivo. *Carcinogenesis* 29, 1587–1593, doi: 10.1093/carcin/bgn052 (2008).
3. Nguyen, D. X., Bos, P. D. & Massague, J. Metastasis: from dissemination to organ-specific colonization. *Nat Rev Cancer* 9, 274–284, doi: 10.1038/nrc2622 (2009).
4. Nishida, N. & Goel, A. Genetic and epigenetic signatures in human hepatocellular carcinoma: a systematic review. *Carr Genomics* 12, 130–137, doi: 10.2174/138920211795654359 (2011).
5. van Zijl, F. et al. Epithelial-mesenchymal transition in hepatocellular carcinoma. *Future Oncol* 5, 1169–1179, doi: 10.2217/fon.09.91 (2009).
6. Llovet, J. M. & Bruix, J. Molecular targeted therapies in hepatocellular carcinoma. *Hepatology* 48, 1312–1327, doi: 10.1002/hep.22506 (2008).
7. Khare, S., Zhang, Q. & Ibda, J. A. Epigenetics of hepatocellular carcinoma: role of microRNA. *World J Gastroenterol* 19, 5439–5445, doi: 10.3748/wjg.v19.i33.5439 (2013).
8. Blume-Jensen, P. & Hunter, T. Oncogenic kinase signalling. *Nature* 411, 355–365, doi: 10.1038/35077225 (2001).
9. Pawson, T. & Scott, J. D. Protein phosphorylation in signaling—50 years and counting. *Trends Biochem Sci* 30, 286–290, doi: 10.1016/j.tibs.2005.04.013 (2005).
10. Ubersax, J. A. & Ferrell, J. E., Jr. Mechanisms of specificity in protein phosphorylation. *Nat Rev Mol Cell Biol* 8, 530–541, doi: 10.1038/nrm2203 (2007).
11. Yaffe, M. B. et al. Sequence-specific and phosphorylation-dependent proline isomerization: a potential mitotic regulatory mechanism. *Science* 278, 1957–1960 (1997).
12. Ranganathan, R., Lu, K. P., Hunter, T. & Noel, J. P. Structural and functional analysis of the mitotic rotamase Pin1 suggests substrate recognition is phosphorylation dependent. *Cell* 89, 875–886 (1997).
13. Lu, P. J., Zhou, X. Z., Shen, M. & Lu, K. P. Function of WW domains as phosphosine- or phosphothreonine-binding modules. *Science* 283, 1325–1328 (1999).
14. Lu, P. J., Wulf, G., Zhou, X. Z., Davies, P. & Lu, K. P. The prolyl isomerase Pin1 restores the function of Alzheimer-associated phosphorylated tau protein. *Nature* 399, 784–788, doi: 10.1038/21650 (1999).
15. Zhou, X. Z. et al. Pin1-dependent prolyl isomerization regulates dephosphorylation of Cdc25C and tau proteins. *Mol Cell* 6, 873–883 (2000).
16. Zhou, X. Z., Lu, P. J., Wulf, G. & Lu, K. P. Phosphorylation-dependent prolyl isomerization: a novel signaling regulatory mechanism. *Cell Mol Life Sci* 56, 788–806 (1999).
17. Wei, S. et al. Active Pin1 is a key target of all-trans retinoic acid in acute promyelocytic leukemia and breast cancer. *Nat Med* 21, 457–466, doi: 10.1038/nm.3839 (2015).
18. Nakamura, K. et al. Proline isomer-specific antibodies reveal the early pathogenic tau conformation in Alzheimer’s disease. Cell 149, 232–244, doi:10.1016/j.cell.2012.02.016 (2012).
19. Kondo, A. et al. Antibody against early driver of neurodegeneration cis P-tau blocks brain injury and tauopathy. Nature 523, 431–436, doi:10.1038/nature14658 (2015).
20. Liou, Y. C., Zhou, X. Z. & Lu, K. P. Prolyl isomerase Pin1 as a molecular switch to determine the fate of phosphoproteins. Trends Biochem Sci 36, 501–514, doi:10.1016/j.tibs.2011.07.001 (2011).
21. Luo, M. L. et al. Prolyl isomerase Pin1 acts downstream of miR200c to promote cancer stem-like cell traits in breast cancer. Cancer Res 74, 3653–3661, doi:10.1158/0008-5472.CAN-13-2785 (2014).
22. Zhang, X., Zhang, B., Gao, J., Wang, X. & Liu, Z. Regulation of the microRNA 200b (miRNA-200b) by transcriptional regulators PEA3 and ELK-1 protein affects expression of Pin1 protein to control anokinesis. J Biol Chem 288, 32742–32752, doi:10.1074/jbc.M113.478016 (2013).
23. He, J. et al. Overexpression of Pin1 in non-small cell lung cancer (NSCLC) and its correlation with lymph node metastases. Lung Cancer 56, 51–58, doi:10.1016/j.lungcan.2006.11.024 (2007).
24. Kim, C. J. et al. Pin1 overexpression in colorectal cancer and its correlation with aberrant beta-catenin expression. World J Gastroenterol 11, 5006–5009 (2005).
25. Ayala, G. et al. The prolyl isomerase Pin1 is a novel prognostic marker in human prostate cancer. Cancer Res 63, 6244–6251 (2003).
26. Pang, R. W. et al. PIN1 expression contributes to hepatic carcinogenesis. J Pathol 210, 19–25, doi:10.1002/path.2024 (2006).
27. Li, Q. et al. The rs2233678 polymorphism in PIN1 promoter region reduced cancer risk: a meta-analysis. PLoS One 8, e68148, doi:10.1371/journal.pone.0068148 (2013).
28. Zhou, X. Z. & Lu, K. P. The isomerase PIN1 controls numerous cancer-driving pathways and is a unique drug target. Nat Rev Cancer 16, 463–478, doi:10.1038/nrc2016.49 (2016).
29. Pang, R. et al. PIN1 overexpression and beta-catenin gene mutations are distinct oncogenic events in human hepatocellular carcinoma. Oncogene 23, 4182–4186, doi:10.1038/sj.onc.1207493 (2004).
30. Ao, R., Zhang, D. R., Du, Y. Q. & Wang, Y. Expression and significance of Pin1, beta-catenin and cyclin D1 in hepatocellular carcinoma. Mol Med Rep 10, 1893–1898, doi:10.3892/mmr.2014.2456 (2014).
31. Pang, R. et al. PIN1 interacts with a specific serine-proline motif of hepatitis B virus X-protein to enhance hepatocarcinogenesis. Gastroenterology 132, 1088–1103, doi:10.1053/j.gastro.2006.12.030 (2007).
32. Liao, X.-H. et al. Chemical or genetic Pin1 inhibition exerts potent anticancer activity against hepatocellular carcinoma by blocking multiple cancer-driving pathways. Sci. Rep. 7, 43693, doi:10.1038/srep43693 (2017).
33. Sun, H. L. et al. ERK Activation Globally Downregulates miRNAs through Phosphorylating Exportin-5. Cancer Cell 30, 723–736, doi:10.1016/j.ccell.2016.10.001 (2016).
34. Ryo, A. et al. PIN1 Is an E2F Target Gene Essential for Neu/Ras-Induced Transformation of Mammary Epithelial Cells. Molecular and Cellular Biology 22, 5281–5295, doi:10.1128/mcb.22.15.5281-5295.2002 (2002).
35. Lee, T. H. et al. Death-associated protein kinase 1 phosphorylates Pin1 and inhibits its prolyl isomerase activity and cellular function. Mol Cell 42, 147–159, doi:10.1016/j.molcel.2011.03.005 (2011).
36. Fang, R. et al. Prolyl isomerase Pin1 is an E2F target gene essential for Neu/Ras-induced transformation of mammary epithelial cells. Mol. Cell Biol. 22, 704–714, doi:10.1038/nrg2634 (2009).
37. Calin, G. A. et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci USA 101, 2999–3004, doi:10.1073/pnas.0307323101 (2004).
38. Mendell, J. T. MicroRNAs: critical regulators of development, cellular physiology and malignancy. Cell Cycle 4, 1179–1184, doi:10.4161/cc.4.9.20323 (2005).
39. Liu, W. R., Shi, Y. H., Peng, Y. F. & Fan, J. Epigenetics of hepatocellular carcinoma: a new horizon. Chin Med J (Engl) 125, 2349–2360 (2012).
40. Melo, S. A. & Kalluri, R. Molecular pathways: microRNAs as cancer therapeutics. Clin Cancer Res 18, 4234–4239, doi:10.1158/1078-0432.CCR-11-2010 (2012).
41. Xu, M. et al. Overexpression of PIN1 Enhances Cancer Growth and Aggressiveness with Cyclin D1 Induction in EBV-Associated Nasopharyngeal Carcinoma. PLoS One 11, e0156833, doi:10.1371/journal.pone.0156833 (2016).
42. Shinoda, K. et al. PIN1 facilitates NF-kappaB activation and promotes tumour progression in human hepatocellular carcinoma. Br J Cancer 113, 1323–1331, doi:10.1038/bjc.2015.272 (2015).
43. Friedl, P. & Wolf, K. Tumour-cell invasion and migration: diversity and escape mechanisms. Nat Rev Cancer 3, 362–374, doi:10.1038/nrc1075 (2003).
44. He, L. & Hannon, G. J. MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet 5, 522–531, doi:10.1038/nrg1379 (2004).
45. Liu, Y. C. et al. Loss of Pin1 function in the mouse causes phenotypes resembling cyclin D1-null phenotypes. Proc Natl Acad Sci USA 99, 1353–1356, doi:10.1073/pnas.0240499 (2002).
46. Lu, Z. & Hunter, T. Prolyl isomerase Pin1 in cancer. Cell Res 24, 1033–1049, doi:10.1038/cr.2014.109 (2014).
47. Liu, Y. et al. Peptidyl-prolyl cis-trans isomerase Pin1 is critical for the regulation of PKB/Akt stability and activation phosphorylation. Oncogene 28, 2436–2445, doi:10.1038/onc.2009.98 (2009).
48. Luo, M. L. et al. The Rab2A GTPase promotes breast cancer stem cells and tumorigenesis via Erk signalling activation. Cell Rep 11, 111–124, doi:10.1016/j.celrep.2015.03.002 (2015).
49. Wolf, G., Garg, P., Liu, Y. C., Iglhart, D. & Lu, K. P. Modeling breast cancer in vivo and ex vivo reveals an essential role of Pin1 in tumorigenesis. EMBO J 35, 3397–3407, doi:10.15252/embj.201603230 (2014).
50. Bostwick, D. G. & Brawer, M. K. Prostatic intra-epithelial neoplasia and early invasion in prostate cancer. Cancer 59, 788–794 (1987).
51. Atkinson, G. P. et al. The prolyl isomerase Pin1 regulates the NF-kappaB signaling pathway and interleukin-8 expression in glioblastoma. Oncogene 28, 3735–3745, doi:10.1038/onc.2009.232 (2009).
52. Cheng, C. W. et al. PIN1 inhibits apoptosis in hepatocellular carcinoma through modulation of the antiapoptotic function of survivin. Am J Pathol 182, 765–775, doi:10.1016/j.ajpath.2012.11.034 (2013).
53. Wang, X. W., Heggard, N. H. & Orum, H. MicroRNAs in liver disease. Gastroenterology 142, 1431–1443, doi:10.1053/j. gastro.2012.04.007 (2012).
60. Song, J. H. & Meltzer, S. J. MicroRNAs in pathogenesis, diagnosis, and treatment of gastroesophageal cancers. *Gastroenterology* **143**, 35–47 e32, doi: 10.1053/j.gastro.2012.05.003 (2012).

61. Takata, A. *et al.* MicroRNA-140 acts as a liver tumor suppressor by controlling NF-kappaB activity by directly targeting DNA methyltransferase 1 (Dnmt1) expression. *Hepatology* **57**, 162–170, doi: 10.1002/hep.26011 (2013).

62. Pais, H. *et al.* Analyzing mRNA expression identifies Smad3 as a microRNA-140 target regulated only at protein level. *RNA* **16**, 489–494, doi: 10.1261/rna.1701210 (2010).

63. Abdel-Rahman, W. M. *et al.* Somatic FGFR9 mutations in colorectal and endometrial carcinomas associated with membranous beta-catenin. *Hum Mutat* **29**, 390–397, doi: 10.1002/humu.20653 (2008).

64. Lan, H., Chen, W., He, G. & Yang, S. *miR-140-5p inhibits ovarian cancer growth partially by repression of PDGFRA*. *Biomed Pharmacother* **75**, 117–122, doi: 10.1016/j.biopha.2015.07.035 (2015).

65. Zhao, H., Fei, A., Shu, Y., Wu, S. & Ju, J. Inhibition of colorectal cancer stem cell survival and invasive potential by hsa-miR-140–5p mediated suppression of Smad2 and autophagy. *Oncotarget* **6**, 19735–19746, doi: 10.18632/oncotarget.3771 (2015).

66. Li, W. & He, F. Monocyte to macrophage differentiation-associated (MMD) targeted by miR-140–5p regulates tumor growth in non-small cell lung cancer. *Biochem Biophys Res Commun* **450**, 844–850, doi: 10.1016/j.bbrc.2014.06.075 (2014).

67. Kai, Y., Peng, W., Ling, W., Jiebing, H. & Zhaan, B. Reciprocal effects between microRNA-140-5p and ADAM10 suppress migration and invasion of human tongue cancer cells. *Biochem Biophys Res Commun* **448**, 308–314, doi: 10.1016/j.bbrc.2014.02.032 (2014).

68. Yu, F. *et al.* let-7 regulates self renewal and tumorigenicity of breast cancer cells. *Cell* **131**, 1109–1123, doi: 10.1016/j.cell.2008.03.027 (2008).

69. Mani, S. A. *et al.* The epithelial-mesenchymal transition generates cells with properties of stem cells. *Cell* **133**, 704–715, doi: 10.1016/j.cell.2008.03.027 (2008).

**Acknowledgements**

This work was supported by the National Natural Science Foundation of China (No. U1205024), the National Natural Science Foundation of China (No. 81171972), the Collaborative Innovation Center for Stem Cells Translational Medicine (Fujian 2011 Program), the Fujian Province Natural Science Fund (No. 2016J01360) and National Institutes of Health grant R01CA167677.

**Author Contributions**

X.X.Y. and H.K.L. developed the concepts, approaches and prepared the manuscript prior to submission. X.X.Y., D.M.C. and L.W. helped to analyze the data. J.F.L. and X.L.L. helped to perform the experiments. X.Z.Z., K.P.L. and H.K.L. developed the concepts, prepared and revised the manuscript prior to submission. All authors approve the final manuscript.

**Additional Information**

*Supplementary information* accompanies this paper at http://www.nature.com/srep

**Competing Interests:** Dr. Lu and Dr. Zhou are inventors of Pin1 technology, which was licensed by BIDMC to Pinteon Therapeutics. Both Dr. Lu and Dr. Zhou own equity in, and consult for, Pinteon. Their interests were reviewed and are managed by BIDMC in accordance with its conflict of interest policy.

**How to cite this article:** Yan, X. *et al.* MicroRNA-140–5p inhibits hepatocellular carcinoma by directly targeting the unique isomerase Pin1 to block multiple cancer-driving pathways. *Sci. Rep.* **7**, 45915; doi: 10.1038/srep45915 (2017).

**Publisher’s note:** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

© The Author(s) 2017